SGMT today
$11.41+$0.52 (+4.78%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minExpanding
Daily trend turns down below $7.51
Key levels
Resistance$20.71
Support$11.40
Support$10.43
Latest news & SEC filings
SEC FilingSagimet Biosciences Inc. filed a report on a major company event (Form 8-K)
ProductSagimet sets 2H 2027 for topline results of its AURORA study in acne
All SGMT news →About Sagimet Biosciences
Sagimet Biosciences is a clinical-stage biopharmaceutical company that creates oral medicines designed to block fatty acid synthase, an enzyme involved in fat production. Its main drug candidate, denifanstat, is being tested for a liver condition marked by fat buildup and scarring, for a common skin condition, and for certain tumors. A second compound, TVB-3567, is in early testing for the skin condition. The company also studies denifanstat alongside another drug for advanced liver disease. It operates chiefly in the United States, while a partner handles development and sales in Greater China.
Based on the company's 10-K filed Mar 11, 2026.
Nasdaq · Healthcare
Sagimet Biosciences Inc. (SGMT)
What Is the Price Target for SGMT?
SEPT Low Target
$22.52
SEPT Mid Target
$26.50
SEPT High Target
$30.47
Analyst Consensus
$26.50
Is SGMT a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SGMT.
Start Free Trial →Is SGMT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, PEG, Analyst Consensus
Fair Value
$20.80
5
Moat Score
NONE
1/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with SGMT?
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SGMT Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-8.97%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for SGMT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SGMT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 12:21:09 | $11.38 | 1,155 | $$13K | SELL |
| 12:13:33 | $11.32 | 1,500 | $$17K | BUY |
| 21:00:48 | $11.41 | 5,138 | $$59K | BUY |
| 20:59:42 | $11.40 | 1,000 | $$11K | MIDPOINT |
| 20:59:33 | $11.41 | 73,139 | $$835K | MIDPOINT |
5 dark pool trades shown · $$935K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for SGMT
PREVIEWSEPT Investing provides real-time options flow tracking for SGMT, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $10 | Jan 15 | 65 | $$1600 | 8 | SWEEP |
| CALL | $10 | Jan 15 | 65 | $$5320 | 28 | SWEEP |
| CALL | $10 | Jan 15 | 65 | $$390 | 2 | SWEEP |
| CALL | $12.5 | Jan 15 | 65 | $$90 | 1 | SWEEP |
| CALL | $12.5 | Nov 20 | 9 | $$660 | 33 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About SGMT
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for SGMT. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $SGMT -- Bullish SGMT at $6.43. Uptrend holds while above $6.32. $8 psychological level is the next resistance to watch. The Play: Watch for a decisive move from current levels with vo...
Join 3,500+ traders discussing SGMT in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Sagimet Biosciences Inc. (SGMT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SGMT — frequently asked questions
What is SGMT stock price today?
Sagimet Biosciences Inc. (SGMT) is at $11.41, up 4.78% (+$0.52) at the Nov 11, 2026 close.
Why is SGMT stock moving today?
Latest SGMT news — Nov 12, 2026: Sagimet Biosciences Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: Sagimet sets 2H 2027 for topline results of its AURORA study in acne
What is the SGMT price target?
The average analyst price target for SGMT is $26.50, ranging from $7 to $56, based on 8 analysts.
What do analysts rate SGMT?
Analyst ratings for SGMT: 1 Buy, 11 Hold, 0 Sell — consensus Hold.
Did SGMT beat earnings?
SGMT last reported on Aug 11, 2026: EPS -$0.26 vs -$0.25 expected — a miss of 3.6%.
Does SGMT pay a dividend?
SGMT does not currently pay a dividend.
What are SGMT support and resistance levels?
Support: $11.40, $10.43, $9.02. Resistance: $20.71.
What are insiders doing with SGMT?
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
What is the latest news on SGMT?
Nov 12, 2026: Sagimet Biosciences Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: Sagimet sets 2H 2027 for topline results of its AURORA study in acne